Evidence map›Paper›PMID 42609421›Full record

ArticleFrontiers in digital health2026

A two-phase digital tool to predict and prevent post-transplant hyperuricemia.

Min Wu, Limian Liang, Tian Tian, Chao Chen, Zongqiang Lai, Yunni Yu, Yourou Zheng, Wei Li, Shiyun Chen, Tian He and 5 more

Abstract read
In one paragraph

Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Min Wu *Department of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Limian Liang *Department of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Tian Tian *College of Pharmacy, Shenzhen Technology University, Shenzhen, Guangdong Province, China.
Chao ChenDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Zongqiang LaiDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Yunni YuDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Yourou ZhengDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Wei LiDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Shiyun ChenDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Tian HeDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Wenmei QiaoDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Qijun ChenDepartment of Liver Transplantation, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Zhenping ZhouDepartment of Kidney Transplantation, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Miaona LiuDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.
Haixia SunDepartment of Pharmacy, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-transplant hyperuricemia (PTHU) is a frequent and clinically significant metabolic complication among kidney transplant recipients. Current models lack personalized pre-transplant prevention strategies, and few studies define the optimal tacrolimus level for PTHU prevention. To address this unmet need, we developed and evaluated an integrated digital health tool consisting of a pre-operative risk-prediction algorithm and a post-operative tacrolimus dosing management module. Method: We enrolled 195 kidney transplant recipients. Pre-transplantation laboratory assessments and serial tacrolimus blood-concentration (Ctac) measurements longitudinally were conducted, while documenting adverse events. Logistic regression was used to identify the risk factors, and then incorporated into a nomogram. A subsequent dosing optimization algorithm was derived from these results. Results: We identified four independent risk factors-standard deviation of red blood cell distribution width (RDW-SD), prothrombin time activity (PTA), serum calcium, and Ctac. Notably, the model achieved strong discriminative performance, with AUROCs of 0.802 (95% CI 0.723-0.881, Conclusion: This study provides a pre-operative risk prediction model and a post-operative dosing tool that, used in tandem, can aid in the prevention of PTHU and the protection of renal allograft function.

Indexed as

clinical decision supportpersonalized medicinepost-transplant hyperuricemiarisk predictiontacrolimus

Identifiers

PMID42609421
PMCPMC13478219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.